Sareum Holdings sees full-year profit ahead of market expectations
Sareum Holdings said on Tuesday that it expects full-year profit and cash at bank to be ahead of market expectations.
FTSE AIM All-Share
739.68
15:00 07/10/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,227.56
15:00 07/10/24
0.54%
119.32
Sareum Holdings
28.00p
13:50 07/10/24
1.82%
0.50p
The AIM-listed specialist cancer drug discovery and development business will provide an update on progress with its cancer and autoimmune disease research and development programmes in mid-late October 2017, which is when it expects to report its full year results.
At 1000 BST, the shares were up 10.5% to 0.83p.